Register by January 23
& save up to **$300**

33rd Annual

TRI-CON

Precision Medicine Innovation

May 4-5, 2026 | Hotel Nikko | San Francisco, CA

Entering the Age of AI

Conference Programs

TABLE OF CONTENTS

Diagnostics Innovation

- Drivers of Diagnostics Innovation
- At-Home and Point-of-Care Diagnostics
- Direct Access Testing
- AI-Enabled Diagnostics
- Infectious Disease Dx
- Market Access

Artificial Intelligence

- AI Venture and Partnering
- AI-Driven Biomarkers
- Computational Pathology
- Agentic AI: Discovery to Healthcare
- AI in Precision Oncology
- AI for Multi-Omic Analysis

Precision Medicine

- CEOs of Precision Medicine
- Precision Medicine in the Age of AI
- Precision Oncology
- Liquid Biopsy: MRD, MCED, and Biomarkers
- AI and Precision Med Beyond Oncology
- AI-Powered Drug Development

Featured Speakers

Lisa Alderson
CEO, Adela

William G. Morice II
CEO, Mayo Clinic Laboratories

Mara G. Aspinall
Partner, Illumina Ventures

Cecilia Schott
Head, Global Precision Diagnostics, GSK

Ajit Singh
CEO, Harbinger Health

Julia Cheek
CEO, Everlywell

Jenny Rooke
Managing Director, Genoa Ventures

Samraat Raha
CEO, Myriad Genetics

33rd Annual

TRI-CON

Precision Medicine Innovation

May 4-5, 2026 | Hotel Nikko | San Francisco, CA

Table-of-Contents

> **The TRICON is a great forum for sharing trends and scientific methods in Medicinal Therapies!**
>
> *Solution Consultant, Elsevier, LTD*

Conference Programs

Diagnostics Innovation

- Drivers of Diagnostics Innovation
- At-Home and Point-of-Care Diagnostics
- Direct Access Testing
- AI-Enabled Diagnostics
- Infectious Disease Dx
- Market Access

Artificial Intelligence

- AI Venture and Partnering
- AI-Driven Biomarkers
- Computational Pathology
- Agentic AI: Discovery to Healthcare
- AI in Precision Oncology
- AI for Multi-Omic Analysis

Precision Medicine

- CEOs of Precision Medicine
- Precision Medicine in the Age of AI
- Precision Oncology
- Liquid Biopsy: MRD, MCED, and Biomarkers
- AI and Precision Med Beyond Oncology
- AI-Powered Drug Development

Connecting Executives, Investors, Entrepreneurs, and Research Thought Leaders to Enable Innovation

Join us for an exclusive gathering of senior-level investors, pharma executives, entrepreneurs, research thought leaders, and innovators at the 33rd Annual TRI-CON. Connect with investors and partners at intimate networking sessions; gain strategic insights on funding activities, business development, and innovation strategies in diagnostics, precision medicine, and AI from industry-led panels; and hear candid perspectives and business recommendations from key opinion leaders during dynamic fireside chats. Building on a 30+ year track record, TRI-CON is positioned as the premier meeting place for key stakeholders to foster meaningful connections, acquire valuable strategic insights, and drive innovation and collaboration. Returning to San Francisco in 2026!

2025

Attendee Demographics



57% Executive
20% Scientist
16% Sales & Marketing
6% Manager
1% Other



47% Biotech/Commercial
14% Pharma
21% Healthcare
7% Academic
2% Services
2% Financial
2% Societies

Sponsor & Exhibit Opportunities

Exhibitors will have an opportunity to enjoy in-person and virtual facilitated networking opportunities with qualified delegates, making it the perfect platform to launch a new product, collect feedback, and generate new leads from around the world.

How Sponsoring/Exhibiting Promotes & Benefits Your Business:

- Generate qualified leads consisting of actual decision-makers from within your focus area
- Network with senior-level professionals and generate leads during dedicated exhibit hall hours, lunches, etc.
- Promote your company's participation in the Event Materials—including contact information and 50-word description
- Increase your brand awareness and drive traffic to your website through our various marketing campaigns
- Increase dedicated networking time in the exhibit hall

Podium Presentations

Available within Main Agenda!

Showcase your solutions to a guaranteed, targeted audience through a 12- or 25-minute presentation during a specific conference program or lunch. Package includes exhibit space, onsite branding, and access to cooperative marketing efforts by CHI. For the luncheon option, lunches are delivered to attendees already seated in the main session room. Presentations do sell out early.

Exhibit Hall Networking Reception Sponsorship

Your company will be recognized as the exclusive sponsor of the Welcome Reception on day 1 to be held in the Exhibit Hall. Use this lively social occasion to launch a new product or solution and drive delegates to your exhibit booth.

Additional sponsorship & branding opportunities include:

- Lanyards
- Foot Trails
- Keynote Chair Drop
- Tote Bag Exclusive Sponsorship
- Water Bottles
- Conference Notebooks
- Tote Bag Insert
- Chair Drop in Session Room

One-on-One Meetings

Work with us to identify your target prospects and we will schedule meetings for you. Think of us as your inside sales team with all your hottest leads in close reach. Opportunities sold on a very limited basis.

Invitation-Only Dinner/Hospitality Suite

Sponsors will select their top prospects from the conference preregistration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations, conduct follow-up, and confirm attendees. The evening will be customized to meet with your specific objectives.

How will CHI ensure that delegates visit the exhibit hall?

- Welcome receptions
- Refreshment breaks
- Raffles and more

For additional information, please contact:

Jon Stroup
Lead Business Development Manager
617-838-5006
jons@healthtech.com

Thank You to Our Sponsors

CORPORATE SPONSORS

GENOLUTION

GENOMENON

MEDIA PARTNERS

Official Publication

Diagnostics World

Lead Sponsoring Publications

Bio-IT World

CLINICAL RESEARCH NEWS
Clinical Trials to the Clinic

GEN
Genetic Engineering & Biotechnology News

INSIDE PRECISION MEDICINE

Sponsoring Publications

American Pharmaceutical Review

DDN Exploring Drug Discovery and Development

Pharmaceutical Outsourcing

TheScientist
Exploring Life, Inspiring Innovation

Sponsoring Associations

Biocompare
The Buyer's Guide for Life Scientists

labcompare

Plenary Keynote Program

MONDAY, MAY 4

PLENARY KEYNOTE SESSION: THE AGE OF ARTIFICIAL INTELLIGENCE: PRECISION MEDICINE VENTURE AND INNOVATION

8:30 Organizer's Welcome Remarks

8:35 Chairperson's Remarks
Charity Williams, Partner, Cooley LLP

8:40 Keynote Introduction *(Sponsorship Opportunity Available)*

8:45 PLENARY KEYNOTE PANEL DISCUSSION: Tech Titans, Investors, and Innovators: How AI Is Driving Precision Medicine Forward

Moderator: Charity Williams, Partner, Cooley LLP

Join leading venture investors and AI innovators as they explore how artificial intelligence is driving the next generation of personalized healthcare. This discussion will uncover emerging investment theses and the critical role of partnerships between technology platforms, startups, and providers in shaping the future of precision medicine.

Panelists:

Milad Alucozai, DrPH, Co-Founder & General Partner, Pamir Ventures

Noosheen Hashemi, Founder & CEO, January AI

Ujjwal Ratan, Head of ML and Data Science, Healthcare & Life Sciences, Amazon Web Services

Joe Shonkwiler, MD, Lead, Healthcare and Life Sciences, Venture Capital BD, Google

PLENARY KEYNOTE SESSION

3:50 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

3:55 Keynote Introduction *(Sponsorship Opportunity Available)*

4:00 Presentation to be Announced

4:30 PLENARY KEYNOTE PANEL DISCUSSION: The Tipping Point: CEOs on the Future of Precision Medicine

Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

As precision medicine accelerates across oncology, population health, and consumer diagnostics, industry leadership is critical to translating innovation into real-world impact. In this session, Mara Aspinall hosts a CEO panel for a candid discussion on the technologies reshaping early detection, decentralized testing, genomic architecture analysis, and the expanding role of AI in powering more accurate and accessible care.

Panelists:

Lisa Alderson, CEO, Adela, Inc.

Julia Cheek, CEO and Founder, Everlywell

TUESDAY, MAY 5

PLENARY KEYNOTE SESSION

8:30 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

8:35 Keynote Introduction *(Sponsorship Opportunity Available)*

8:40 PLENARY KEYNOTE PANEL DISCUSSION: Intelligence & Impact: The Age of Diagnostic Innovation

Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

Diagnostics is entering a moment of rapid change, fueled by new technologies, evolving patient needs, and the growing influence of AI. In this keynote session, Mara hosts a panel of industry leaders to discuss how they are driving innovation within their own organizations—from advancing early detection to expanding decentralized testing and building smarter, AI-enabled laboratory systems. The conversation will explore the practical steps these leaders are taking today.

Panelists:

William G. Morice II, MD, PhD, President & CEO, Mayo Clinic Laboratories; Professor & Past Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic; Chair, American Clinical Laboratory Association Board of Directors

Ajit Singh, PhD, CEO, Harbinger Health

Megann Vaughn Watters, Vice President, New Ventures & Strategic Alliances, Labcorp

Jenny Rooke, Founder & Managing Director, Genoa Ventures

TABLE OF CONTENTS

33rd Annual TRI-CON Precision Medicine Innovation

2026 Featured Speakers

Lisa Alderson
CEO, Adela

Ajit Singh
CEO, Harbinger Health

Mara G. Aspinall
CEO
Partner, Illumina Ventures

William G. Morice II
VP, Global Commercial Precision Medicine
CEO, Mayo Clinic Laboratories

Cecilia Schott
Head, Global Precision Diagnostics, GSK

Ian McCaffery
Global Head, Precision Medicine, AbbVie

Jenny Rooke
Managing Director
Genoa Ventures

Samraat Raha
CEO, Myriad Genetics

Julia Cheek
CEO, Everlywell

Milad Alucozai
General Partner, Pamir Ventures

Noosheen Hashemi
CEO, January AI

Michael Snyder
Director, Personalized Medicine, Stanford

Amy Summy
Chief Marketing Officer, Labcorp

Kyle Farh
VP, AI Lab, Illumina

Joe Shonkwiler
Lead, Healthcare, Venture, Google

Arturo Loaiza-Bonilla
Co-Founder, Massive Bio

Mike Zack
CEO, PGxAI

Ezra Cohen
CMO, Oncology, Tempus Labs

Alex Aravanis
CEO, Moonwalk Biosciences

Colin Hill
CEO, Aitia Bio

15th Annual

Diagnostics Innovation

At-Home, Point-of-Care, and Direct Access Testing



May 4-5, 2026

MONDAY, MAY 4

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION: THE AGE OF ARTIFICIAL INTELLIGENCE: PRECISION MEDICINE VENTURE AND INNOVATION

8:30 Organizer's Welcome Remarks

8:35 Chairperson's Remarks
Charity Williams, Partner, Cooley LLP

8:40 Keynote Introduction *(Sponsorship Opportunity Available)*

8:45 PLENARY KEYNOTE PANEL DISCUSSION: Tech Titans, Investors, and Innovators: How AI Is Driving Precision Medicine Forward

Moderator: Charity Williams, Partner, Cooley LLP
Join leading venture investors and AI innovators as they explore how artificial intelligence is driving the next generation of personalized healthcare. This discussion will uncover emerging investment theses and the critical role of partnerships between technology platforms, startups, and providers in shaping the future of precision medicine.
Panelists:
Milad Alucozai, DrPH, Co-Founder & General Partner, Pamir Ventures
Noosheen Hashemi, Founder & CEO, January AI
Ujjwal Ratan, Head of ML and Data Science, Healthcare & Life Sciences, Amazon Web Services
Joe Shonkwiler, MD, Lead, Healthcare and Life Sciences, Venture Capital BD, Google

9:30 Networking Coffee Break with Exhibit Viewing

EMPOWERED CONSUMER: AT-HOME AND DIRECT ACCESS TESTING

10:10 Chairperson's Remarks
Mickey Urdea, PhD, Founder & Partner, Halteres Associates, LLC

10:15 Diagnostics are Leaving the Lab and the Physicians Behind—Is the Hyperconvenient Testing Ecosystem Ready?
Michael J. Mina, MD, PhD, CSO, YourBio Health
The rapid movement of diagnostics out of traditional laboratories, and outside traditional provider ordering, is transforming how patients access and act on their own health information. In an increasingly hyperpersonalized world, the public is demanding greater convenience, but convenience alone is not enough. A new ecosystem is required to support safe, hyper-convenient testing. This talk discusses what's needed for diagnostics to keep pace with our fast-changing, hyper-personalized ecosystems.

10:30 MB-CasFire: An Engineered CRISPR Enzyme for Diagnostic Applications
James Broughton, PhD, Senior Director, Head of Research, Mammoth Biosciences, Inc.

10:45 At-Home Access to Diagnostics Testing: DIY Sampling and Shipment or DIY Testing?
Mickey Urdea, PhD, Founder & Partner, Halteres Associates, LLC
At-home access to laboratory quality diagnostic testing has taken two separate paths that don't require patients to visit a clinic. The first is home collection and shipment of samples to a central lab, while the second is to collect samples and perform tests at the patient's home. We will explore the pathways, types of testing involved, methods used, examples of technologies, benefits, issues, and trends.

11:00 PANEL DISCUSSION: Experiences with Home Access to Testing: Where Are We?
Moderator: Mickey Urdea, PhD, Founder & Partner, Halteres Associates, LLC
The panel of experts has different perspectives of home access to diagnostic testing, including from the labs testing home collected samples and from the providers of tools for use at home for DIY collection of samples for shipment or home testing. They will discuss their experiences and innovations and how they believe the access to testing without patient visits to draw stations or clinics will change with time.
Panelists:
Elizabeth M. Marlowe, PhD, D(ABMM), Executive Scientific Director, Head, R&D, Infectious Diseases & Immunology, Quest Diagnostics
Michael J. Mina, MD, PhD, CSO, YourBio Health
Amy Summy, Executive Vice President and Chief Marketing Officer, Labcorp

11:45 Sponsored Presentation *(Opportunity Available)*

12:10 pm Networking Luncheon

12:50 Networking Dessert Break with Exhibit Viewing

FUTURE OF POINT-OF-CARE DIAGNOSTICS

1:20 Chairperson's Remarks
Michael W. Ryan, Partner, McDermott Will & Schulte LLP

1:25 Bridging the Lab and the Living Room: The Future of Molecular Diagnostics at the Point of Care
Bill Hyun, PhD, Venture Partner, Genoa Ventures
Dr. William Hyun will explore how next-generation molecular diagnostic platforms are redefining accessibility, accuracy, and affordability in healthcare. Drawing from more than two decades of experience advancing cytometry, genomics, and clinical technologies, he will highlight the convergence of precision lab science with point-of-care and at-home testing. The talk will showcase pathways for translating complex molecular assays into deployable systems that deliver real-world impact.

1:40 Ensuring Access for Point-of-Care Diagnostics: Addressing Payer Site of Service Restrictions
Brock Schroeder, PhD, Vice President, Market Access, Cepheid
This session will explore one of the key challenges facing developers of POC diagnostics—site of service restrictions that restrict coverage and reimbursement of some POC tests in certain sites of care (e.g., physician offices). While Payers may implement these policies for cost control, they can have unintended consequences for patient care. Attendees will gain actionable insights into the current state of site of service challenges.

1:55 Breaking Barriers: Policy and Reimbursement Strategies for Point-of-Care Diagnostics

Nakiya Parkes, MBA, MPH, CHES, Director of Health Policy & Market Access, Global Market Access, Biomerieux

This session will explore innovative policy frameworks and reimbursement strategies that enable broader adoption of point-of-care diagnostics. By addressing regulatory challenges and payer considerations, we aim to highlight practical solutions that improve patient access and reduce healthcare costs. Attendees will gain actionable insights into aligning clinical innovation with sustainable reimbursement models.

2:10 PANEL DISCUSSION: Point-of-Care Molecular Diagnostics: Policy Barriers and Proposed Pathways & Solutions

Moderator: Michael W. Ryan, Partner, McDermott Will & Schulte LLP

Point-of-care molecular diagnostics offer safe, effective testing at the time of treatment. However, policy and reimbursement frameworks often lag behind the science. This panel will explore key barriers limiting broader adoption of POC molecular tests, and outline practical pathways to overcome them. Panelists will discuss real-world experience navigating reimbursement challenges, investor perspectives on what it takes to build sustainable POC business, and payer viewpoints on value assessment and coverage.

2:55 Sponsored Presentation *(Opportunity Available)*

3:20 Networking Refreshment Break with Exhibit Viewing

PLENARY KEYNOTE SESSION

3:50 Chairperson's Remarks

Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

3:55 Keynote Introduction *(Sponsorship Opportunity Available)*

4:00 Presentation to be Announced

4:30 PLENARY KEYNOTE PANEL DISCUSSION: The Tipping Point: CEOs on the Future of Precision Medicine



Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

As precision medicine accelerates across oncology, population health, and consumer diagnostics, industry leadership is critical to translating innovation into real-world impact. In this session, Mara Aspinall hosts a CEO panel for a candid discussion on the technologies reshaping early detection, decentralized testing, genomic architecture analysis, and the expanding role of AI in powering more accurate and accessible care.

Panelists:
Lisa Alderson, CEO, Adela, Inc.
Julia Cheek, CEO and Founder, Everlywell

5:15 Networking Welcome Reception with Exhibit Viewing

6:15 Close of Day

TUESDAY, MAY 5

8:00 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Chairperson's Remarks

Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

8:35 Keynote Introduction *(Sponsorship Opportunity Available)*

8:40 PLENARY KEYNOTE PANEL DISCUSSION: Intelligence & Impact: The Age of Diagnostic Innovation





Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

Diagnostics is entering a moment of rapid change, fueled by new technologies, evolving patient needs, and the growing influence of AI. In this keynote session, Mara hosts a panel of industry leaders to discuss how they are driving innovation within their own organizations—from advancing early detection to expanding decentralized testing and building smarter, AI-enabled laboratory systems. The conversation will explore the practical steps these leaders are taking today.

Panelists:
William G. Morice II, MD, PhD, President & CEO, Mayo Clinic Laboratories; Professor & Past Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic; Chair, American Clinical Laboratory Association Board of Directors
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Ajit Singh, PhD, CEO, Harbinger Health
Megann Vaughn Watters, Vice President, New Ventures & Strategic Alliances, Labcorp

9:20 Transition to Sessions

HOW AI IS TRANSFORMING DIAGNOSTICS

9:25 Chairperson's Remarks

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF Clinical Microbiology Laboratory; Chan-Zuckerberg Biohub Investigator, UCSF School of Medicine

9:30 AI across the Diagnostics Lifecycle: Analytical Precision, Clinical Stewardship, Discovery, and Enterprise Acceleration

Sivan Bercovici, PhD, CTO & Chief Business Officer, Karius, Inc.

Karius has built the largest microbial cell-free DNA datasets, increasingly linked to clinical context, enabling AI across the platform. Analytical AI refines identification, quantification, and resistance inference from fragmented DNA. Interpretive AI integrates results with clinical context to guide impactful use. Discovery AI uncovers signals beyond infection, including autoimmune disease activity. Organizational AI enhances engineering, scientific review, and workflows—illustrating Karius's leadership in advancing clinically meaningful, innovative applications of AI.

9:45 AI for Real-Time Interpretation of Acute Inflammation: Precision Medicine for Hospital Care

Timothy Sweeney, MD, PhD, Co-Founder & CEO, Inflammatix, Inc.

Oncology care was transformed by high-dimensional molecular diagnostics to distinguish disease from mimics, stage progression, and guide therapy. Acute care faces similar biological complexity but lacks this structure. This talk examines how AI applied to high-dimensional immune-expression data—using TriVerity as a case study—can bring staging logic to acute illness, turning molecular patterns into real-time insight that supports critical decisions when diagnosis alone is not enough.

10:00 AI-Driven Rare Disease Diagnosis

Laura Li, PhD, FACMGG, CEO, Breakthrough Genomics

We will present our Virtual Geneticist platform with AI tools transforming genomic interpretation by automating variant prioritization, evidence aggregation, and phenotype matching. Machine learning models integrate literature, population databases, functional annotations, and patient phenotypes to rank pathogenicity at scale. In addition, we use natural-language processing which accelerates curation from reports. Deployed in clinical pipelines, AI significantly reduces turnaround time, supports reanalysis, and can raise diagnostic yield.

10:15 AI in Action: Translating Innovation into Everyday Healthcare

Ellington West, CEO, Sonavi Labs

10:30 Networking Coffee Break with Exhibit Viewing

INFECTIOUS DISEASE DIAGNOSTICS

11:10 Chairperson's Remarks

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF Clinical Microbiology Laboratory; Chan-Zuckerberg Biohub Investigator, UCSF School of Medicine

11:15 Integrating Host Response and Metagenomics for Precision Diagnosis of Infections

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF Clinical Microbiology Laboratory; Chan-Zuckerberg Biohub Investigator, UCSF School of Medicine

Combining metagenomic next-generation sequencing (mNGS) with host response profiling can improve diagnostic accuracy in complex clinical cases. RNA host response data collected over a decade of cerebrospinal fluid mNGS testing has been leveraged to generate machine-learning based classifiers for infectious—bacterial, fungal, viral, and parasitic—and non-infectious syndromes. The talk will discuss leveraging these classifiers to enhance diagnosis and treatment for critically ill patients with neurologic illness.

11:30 Q-POC: A Portable Sample to Answer High-Plex MDx Device for the Next Generation of Syndromic + AMR Testing at the Point of Need

Jonathan O'Halloran, PhD, Co-Founder & CEO, QuantuMDx

With the rapid emergence of anti-microbial resistance and the clear utility of syndromic testing, high multiplex diagnostics are becoming more valued. However, the reimbursement and willingness to pay issues are not changing to match the advancements in technology. Q-POC has been designed to address the cost issues in multiplexing, without compromising on speed, portability, ease of use, and quality.

11:45 Infectious Disease Diagnostics: Beyond Pathogen Identification

Bradley Murray, MBA, CEO & Co-Founder, Delve Bio

Identifying the causative organism is the most critical task in infectious disease diagnostics. However, that often does not paint the full picture. This talk will outline a framework for what other information infectious disease tests need to deliver to optimally support clinical decision making.

12:00 pm PANEL DISCUSSION: Innovation at the Frontiers of Infectious Disease Diagnostics: Advancing Real-World Care

Moderator: Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF Clinical Microbiology Laboratory; Chan-Zuckerberg Biohub Investigator, UCSF School of Medicine

This panel brings together leaders in the field to discuss how emerging technologies are impacting real-world diagnosis of infectious diseases. Panelists will share their perspectives on how metagenomic sequencing is being used clinically, host response profiling can be leveraged for differential diagnosis, and AI can be incorporated into clinical and laboratory settings to improve test accuracy and clinical decision-making.

Panelists:

Esther Babady, PhD, Senior Vice President, Global Medical Affairs, bioMerieux

Sivan Bercovici, PhD, CTO & Chief Business Officer, Karius, Inc.

Timothy Sweeney, MD, PhD, Co-Founder & CEO, Inflammatix, Inc.

Ephraim L. Tsalik, MD, MHS, PhD, FIDSA, Vice President & CSO, Infectious Disease & Acute Care, Danaher Diagnostics

12:45 Transition to Lunch

12:50 Luncheon Presentation *(Sponsorship Opportunity Available)* **or Enjoy Lunch on Your Own**

1:15 Session Break

MARKET ACCESS FOR ADVANCED DIAGNOSTICS

2:00 Chairperson's Remarks

2:05 Let's Float All Boats

Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus AI

What does innovation in Market Access activities look like? There has always been a bit of a roadmap on how labs approach payers for coverage and reimbursement. The question is if that historical roadmap offers the most efficient approach today. The market is primed for collaboration to address issues that are preventing the value of precision diagnostics from being realized. Collaboration should encompass as many actors as possible.

2:20 Closing Gaps in Coverage: Implementation of State Biomarker Laws

Paul Sheives, MS, JD, Vice President, Government Affairs, Myriad Genetics

2:35 Talk Title to be Announced

Damon Hostin, Head, Global Market Access, Illumina, Inc.

2:50 PANEL DISCUSSION: What's Prior Authorization Got to Do with It?

Moderator: Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus AI

We have been hearing a lot about prior authorization. Is prior authorization really the panacea we are hearing about? In this session we will explore the future of prior authorization. How do we identify appropriate testing, create an approval process and opportunity to audit, and ensure rules are being followed? We will also identify other areas within coverage and reimbursement where innovation would be welcomed.

Panelists:

Damon Hostin, Head, Global Market Access, Illumina, Inc.

Paul Sheives, MS, JD, Vice President, Government Affairs, Myriad Genetics

3:50 Close of Conference

3rd Annual

Artificial Intelligence

Driving Next-Generation Innovation in Healthcare, Diagnostics, and Precision Medicine

May 4-5, 2026

MONDAY, MAY 4

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION: THE AGE OF ARTIFICIAL INTELLIGENCE: PRECISION MEDICINE VENTURE AND INNOVATION

8:30 Organizer's Welcome Remarks

8:35 Chairperson's Remarks
Charity Williams, Partner, Cooley LLP

8:40 Keynote Introduction *(Sponsorship Opportunity Available)*

8:45 PLENARY KEYNOTE PANEL DISCUSSION: Tech Titans, Investors, and Innovators: How AI Is Driving Precision Medicine Forward





Moderator: Charity Williams, Partner, Cooley LLP

Join leading venture investors and AI innovators as they explore how artificial intelligence is driving the next generation of personalized healthcare. This discussion will uncover emerging investment theses and the critical role of partnerships between technology platforms, startups, and providers in shaping the future of precision medicine.

Panelists:
Milad Alucozai, DrPH, Co-Founder & General Partner, Pamir Ventures
Noosheen Hashemi, Founder & CEO, January AI
Ujjwal Ratan, Head of ML and Data Science, Healthcare & Life Sciences, Amazon Web Services
Joe Shonkwiler, MD, Lead, Healthcare and Life Sciences, Venture Capital BD, Google

9:30 Networking Coffee Break with Exhibit Viewing

AI-DRIVEN BIOMARKERS, COMPUTATIONAL PATHOLOGY, AND AGENTIC SYSTEMS FOR CLINICAL TRIALS AND CLINICAL DECISION SUPPORT

10:10 Chairperson's Remarks
Arturo Loaiza-Bonilla, MD, Co-Founder & CMAIO, Massive Bio, Inc.

10:15 AI-Enabled Multidisciplinary Oncology: Multi-Omic Intelligence, Agentic Workflows, and the Clinical-Trial Enrollment Paradox
Arturo Loaiza-Bonilla, MD, Co-Founder & CMAIO, Massive Bio, Inc.

AI-enabled multidisciplinary oncology is advancing rapidly through the integration of pathology, imaging, genomics, and molecular diagnostics. Building on concepts from the ASCO Educational Book, this presentation highlights how multi-agent frameworks—SYNERGY-AI OS and Reticulum Nexus—unify multi-omic data and streamline care. Practical cancer applications will be shown, including core concepts, AI in imaging and pathology, biomarker-driven decision support and resolving the clinical-trial enrollment paradox through AI-driven prescreening and workflow automation.

10:30 From Diagnostic Development to Test Commercialization: How AI and Collaborative Innovation are Transforming Digital Pathology
Paul Beresford, PhD, Senior Vice President, BioPharma Partnerships, PathAI

AI is reshaping the full lifecycle of digital diagnostics from biomarker discovery through development, regulatory approval, commercialization, and clinical adoption. Foundation models accelerate progress by improving accuracy at the outset and reducing data and validation requirements. These advances, combined with close collaboration across pathology, biopharma, and diagnostic organizations, enable scalable and trusted clinical solutions that enhance the effectiveness of pathologists and streamline laboratory workflows.

10:45 Computational Pathology: Is Pharma Driving an Inflection Point?
Gary Gustavsen, PhD, Partner & Managing Director, Health Advances

It seems the field has been 1-2 years away from digital pathology taking hold for the past 15 years. However, now is different. As seen with NGS and liquid biopsy, it isn't until pharma includes new technologies in clinical trials that we see a true inflection point in adoption. This presentation will highlight how the field is changing to support this paradigm shift.

11:00 PANEL DISCUSSION: AI-Driven Precision Medicine: Harnessing Biomarkers, Multimodal Data, and Agentic Systems to Accelerate Drug Development
Moderator: Arturo Loaiza-Bonilla, MD, Co-Founder & CMAIO, Massive Bio, Inc.

AI-driven precision medicine is entering a new era powered by multimodal data fusion, biomarker-guided development, and emerging agentic systems. This panel will explore how integrating genomics, imaging, pathology, and real-world data with orchestrated AI workflows accelerates target discovery, patient selection, and clinical trial execution. Leaders in the field will discuss practical deployment, regulatory considerations, and the future of adaptive, data-driven drug development.

Panelists:
Paul Beresford, PhD, Senior Vice President, BioPharma Partnerships, PathAI
Dean Bitan, CEO, Imagene AI
Gary Gustavsen, PhD, Partner & Managing Director, Health Advances
Guneet Walia, PhD, Senior Director, Data Science and Digital Health, Johnson & Johnson

11:45 Bridging Real-World Evidence Gaps: The Role of Literature-Derived RWE in Rare or Complex Indications GENOMENON
Mark Kiel, CoFounder & CSO, Genomenon

The biomedical literature reflects decades of global clinical practice and millions of patient records, with deep characterization of demographics, clinical features, biomarkers, and genetics. Especially for rare or complex indications, where traditional sources of RWE may lack coverage or sufficient detail, this evidence can fill critical gaps. We reveal how literature-derived RWE can complement other sources and optimize natural history studies, trial design, and label expansion strategies.

12:10 pm Networking Luncheon

12:50 Networking Dessert Break with Exhibit Viewing

OPPORTUNITIES FOR AGENTIC AI TO TRANSFORM PRECISION MEDICINE: FROM DISCOVERY TO HEALTHCARE

1:20 Chairperson's Remarks
Vikram Chaudhery, PhD, Partner, Genoa Ventures

1:25 Agentic AI for Precision Medicine: Integrating Multi-Omics, Clinical Guidelines, and Real-World Evidence
Mike Zack, MD, PhD, CEO & Co-Founder, PGxAI
Integrating agentic AI architectures with multi-omic data and clinical knowledge remains a major challenge in delivering reliable precision-medicine recommendations. This session examines practical approaches for unifying genomic, transcriptomic, and metabolomic signals with guidelines, FDA label logic, and real-world evidence. It highlights opportunities and technical considerations for scalable, privacy-preserving deployment and outlines how such systems can improve therapeutic decisions across diverse clinical environments.

1:40 Talk Title to be Announced
Justin Chen, MD, Clinical Specialist, Google

1:55 Talk Title to be Announced
Michael Blum, MD, Co-Founder & CEO, BeeKeeperAI

2:10 PANEL DISCUSSION: Opportunities for Agentic AI to Transform Precision Medicine: From Discovery to Healthcare
Moderator: Vikram Chaudhery, PhD, Partner, Genoa Ventures
Panelists:
Michael Blum, MD, Co-Founder & CEO, BeeKeeperAI
Justin Chen, MD, Clinical Specialist, Google
Ann DeWitt, PhD, General Partner, Engine Ventures
Rajesh Ramaswamy, PhD, Senior Vice President, Head of Machine Learning and Artificial Intelligence Strategy, Sail Biomedicines
Mike Zack, MD, PhD, CEO & Co-Founder, PGxAI

2:55 Sponsored Presentation *(Opportunity Available)*

3:20 Networking Refreshment Break with Exhibit Viewing

PLENARY KEYNOTE SESSION

3:50 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

3:55 Keynote Introduction *(Sponsorship Opportunity Available)*

4:00 Presentation to be Announced

4:30 PLENARY KEYNOTE PANEL DISCUSSION: The Tipping Point: CEOs on the Future of Precision Medicine



Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
As precision medicine accelerates across oncology, population health, and consumer diagnostics, industry leadership is critical to translating innovation into real-world impact. In this session, Mara Aspinall hosts a CEO panel for a candid discussion on the technologies reshaping early detection, decentralized testing, genomic architecture analysis, and the expanding role of AI in powering more accurate and accessible care.
Panelists:
Lisa Alderson, CEO, Adela, Inc.
Julia Cheek, CEO and Founder, Everlywell

5:15 Networking Welcome Reception with Exhibit Viewing

6:15 Close of Day

TUESDAY, MAY 5

8:00 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

8:35 Keynote Introduction *(Sponsorship Opportunity Available)*

8:40 PLENARY KEYNOTE PANEL DISCUSSION: Intelligence & Impact: The Age of Diagnostic Innovation





Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
Diagnostics is entering a moment of rapid change, fueled by new technologies, evolving patient needs, and the growing influence of AI. In this keynote session, Mara hosts a panel of industry leaders to discuss how they are driving innovation within their own organizations—from advancing early detection to expanding decentralized testing and building smarter, AI-enabled laboratory systems. The conversation will explore the practical steps these leaders are taking today.
Panelists:

William G. Morice II, MD, PhD, President & CEO, Mayo Clinic Laboratories; Professor & Past Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic; Chair, American Clinical Laboratory Association Board of Directors
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Ajit Singh, PhD, CEO, Harbinger Health
Megann Vaughn Watters, Vice President, New Ventures & Strategic Alliances, Labcorp

9:20 Transition to Sessions

ADVANCES IN ARTIFICIAL INTELLIGENCE AND MULTI-OMIC ANALYSIS ENABLING NEXT-GEN PRECISION MEDICINE

9:25 Chairperson's Remarks

9:30 AI for Precision Medicine and Drug Target Discovery
Kyle Farh, MD, PhD, Vice President & Distinguished Scientist, Artificial Intelligence Lab, Illumina

9:45 Gemini Digital Twins, Deep Biological Knowledge, and the Future of Precision Medicine
Colin Hill, CEO, Aitia
The realization of precision medicine in the multiomics age is slower than initially envisioned, primarily due to our still-incomplete knowledge of the complex biological circuitry underlying human health and disease. This is changing, thanks to the convergence of computational power, massive multimodal datasets, and causal AI, resulting in Gemini Digital Twins that accurately model any disease and accelerate precision medicine discovery and development (neurodegeneration and oncology examples will be presented).

10:00 Re-Imagining Disease Risk Prediction with Whole-Genome Based PRS: Driving Earlier, Cost-Effective Care while Improving Outcomes
Premal Shah, PhD, CEO, MyOme
Whole-genome-derived PRS and AI-driven risk models are transforming proactive care. The session reviews advances in accuracy, population-health applications, and clinical workflows that enable earlier detection and targeted interventions. The focus is on how these innovations reduce downstream costs, improve outcomes, and support large-scale preventive health strategies across diverse patient populations.

10:15 From Single Cells to Therapeutic Insight: AI-Driven Multi-Omic Data for Drug Discovery
Amirali Kia, PhD, Vice President, Artificial Intelligence and Data Science, Element Biosciences
Element Biosciences' AVITI24 enables true single-cell multi-omic profiling, capturing transcriptomic, proteomic, and morphological data from the same cell. This integrated view provides deep insight into cellular machinery and responses to perturbations at pathway-level resolution. We present AI-driven approaches that leverage pseudo-bulk representations of single-cell data to reduce noise while preserving biological signal. By mapping pathway activation and deactivation across perturbations, this framework enables systematic profiling and prediction of combinatorial effects.

10:30 Networking Coffee Break with Exhibit Viewing

ADVANCES IN ARTIFICIAL INTELLIGENCE AND MULTI-OMIC ANALYSIS ENABLING NEXT-GEN PRECISION MEDICINE (CONT.)

11:10 Chairperson's Remarks

11:15 Talk Title to be Announced
Ben Busby, PhD, Global Alliances Manager, Omics, NVIDIA

11:30 Adaptive Intelligence in Medicine: Translating Biomarkers to Actionable Care
Andrea Bild, PhD, Director, Cancer Systems Biology Institute, Professor, Medical Oncology & Therapeutics, City of Hope Cancer Center
This presentation will discuss how cutting-edge biomarker discovery and AI modeling are reshaping precision medicine. The discussion will highlight emerging methods that integrate dynamic biomarker signatures with adaptive machine-learning systems to support real-time clinical decision-making. Attendees will gain insight into how next-generation AI can accelerate diagnostics, personalize therapy, and strengthen the resilience of healthcare delivery.

11:45 PANEL DISCUSSION: Advances in Artificial Intelligence and Multi-Omic Analysis Enabling Next-Gen Precision Medicine
Moderator: Ben Busby, PhD, Global Alliances Manager, Omics, NVIDIA
Panelists:
Alex Aravanis, MD, PhD, CEO, Moonwalk Biosciences
Kyle Farh, MD, PhD, Vice President & Distinguished Scientist, Artificial Intelligence Lab, Illumina
Jimmy ChengHo Lin, PhD, CSO, Freenome, Inc.
Premal Shah, PhD, CEO, MyOme

12:45 pm Transition to Lunch

12:50 Luncheon Presentation *(Sponsorship Opportunity Available)* **or Enjoy Lunch on Your Own**

1:15 Session Break

AI FOR PRECISION ONCOLOGY

2:00 Chairperson's Remarks

2:05 Cross Modality Oncology Intelligence: From Biomarkers to Trial Success
Dean Bitan, CEO, Imagene AI

2:20 Explainable AI and Transcriptomic Network Analysis in Precision Oncology
Thomas Brown, MD, CMO, Sygnomics

2:35 Scalable Clinical Inference and Multi-Modal AI Modeling for Predictive Insights from Real-World Oncology Data
Anshu Jain, MD, Chief Business and Clinical Officer, Zephyr AI
We present a modular AI framework that transforms unstructured real-world oncology data into predictive insights using clinical, genomic, and image-based inputs. The platform supports drug response prediction,

immune therapy stratification, and transcriptomic reconstruction from routine diagnostics. Validated across enterprise-scale real-world cohorts, these models uncover clinically meaningful signal from sparse data—enabling precision treatment decisions without new biomarker panels or custom assays.

2:50 When Evidence Breaks: The New Paradigm for Precision Medicine

Steve Brown, Founder & CEO, CureWise

Precision medicine is fragmenting disease into molecular subtypes too small for traditional evidence frameworks, leaving many patients and clinicians without guidance. When trials become impossible and the evidence base breaks, AI offers a new paradigm by integrating diagnostics, mechanistic biology, and real-world signals to generate individualized, continuously updated insight. My own rare cancer case illustrated this shift. Medicine must now evolve from static, cohort-based proof to dynamic, patient-level learning.

3:05 An AI Platform for Predictive Biomarkers to Benefit Every Cancer Patient

Rafael Rosengarten, PhD, CEO, Genialis

Genialis is building an AI therapeutic recommendation engine for every cancer patient. We call this engine the "Genialis Supermodel," comprised of a transcriptomics Foundation Model and a comprehensive library of machine learning algorithms that cover all therapeutically relevant cancer biology. The Supermodel yields a new class of biomarkers to match patients with promising new therapies such as KRAS inhibitors, immune agents, and all other targets/drugs.

3:20 How Functional Precision Medicine and AI Can Transform Cancer Treatment

James Foote, CEO, First Ascent Biomedical

Functional Precision Medicine (FPM) redefines precision oncology by testing live tumor cells against hundreds of FDA-approved drugs to guide individualized therapy. This session explores how integrating functional data with genomic insights enhances predictive accuracy, accelerates clinical decision-making, and bridges translational gaps. Real-world clinical results demonstrate FPM's potential to expand precision medicine access, improve outcomes, and inform regulatory and reimbursement pathways for broader implementation.

3:35 Close of Conference

> **TRICON is an excellent conference with an excellent blend of hot topics and exciting technologies!**
>
> *Resident, Cedar-Sinai*

9th Annual

Precision Medicine

Clinical Implementation of Personalized Medicine, Liquid Biopsy, Biomarkers, and Companion Diagnostics

May 4-5, 2026

MONDAY, MAY 4

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION: THE AGE OF ARTIFICIAL INTELLIGENCE: PRECISION MEDICINE VENTURE AND INNOVATION

8:30 Organizer's Welcome Remarks

8:35 Chairperson's Remarks
Charity Williams, Partner, Cooley LLP

8:40 Keynote Introduction *(Sponsorship Opportunity Available)*

8:45 PLENARY KEYNOTE PANEL DISCUSSION: Tech Titans, Investors, and Innovators: How AI Is Driving Precision Medicine Forward





Moderator: Charity Williams, Partner, Cooley LLP

Join leading venture investors and AI innovators as they explore how artificial intelligence is driving the next generation of personalized healthcare. This discussion will uncover emerging investment theses and the critical role of partnerships between technology platforms, startups, and providers in shaping the future of precision medicine.

Panelists:
Milad Alucozai, DrPH, Co-Founder & General Partner, Pamir Ventures
Noosheen Hashemi, Founder & CEO, January AI
Ujjwal Ratan, Head of ML and Data Science, Healthcare & Life Sciences, Amazon Web Services
Joe Shonkwiler, MD, Lead, Healthcare and Life Sciences, Venture Capital BD, Google

9:30 Networking Coffee Break with Exhibit Viewing

PRECISION MEDICINE AND DRUG DEVELOPMENT IN THE AGE OF AI

10:10 Chairperson's Remarks

10:15 Precision Medicine and Drug Development in the Age of AI
Ian McCaffery, PhD, Vice President and Global Head of Precision Medicine, Translational Research & Companion Diagnostics, AbbVie

10:30 AI in Drug Development: Using AI to Find the Right Patients for the Right Drugs
Andy Moye, PhD, Senior Vice President and General Manager, Data Products, Tempus

Discover how AI-powered lab-in-the-loop techniques are revolutionizing drug discovery by identifying and validating novel therapeutic targets. This presentation explores how our platform enables pharmaceutical partners to query real-world data for patients predicted to respond to inhibition of entirely new targets and early-stage developmental assets—even those not yet in clinical trials. Learn how this approach accelerates target validation and patient stratification, bridging the gap between computational prediction and clinical reality.

10:45 PANEL DISCUSSION: Precision Medicine and Drug Development in the Age of AI
Moderator: Daryl Pritchard, PhD, Senior Vice President, Science Policy, Personalized Medicine Coalition
Panelists:
Ian McCaffery, PhD, Vice President and Global Head of Precision Medicine, Translational Research & Companion Diagnostics, AbbVie
Andy Moye, PhD, Senior Vice President and General Manager, Data Products, Tempus
Jai Pandey, PhD, Head, Global Device Regulatory IVD/CDx and Digital Health, Sanofi
Cecilia Schott, PharmD, MBA, Vice President, Head of Global Precision Diagnostics - Oncology Translational Medicine, GSK

11:45 Automated High-Throughput EV Isolation Enabling Scalable Multiomics Cancer Biomarker Discovery
GENOLUTION
Minlee Kim, CTO, Genolution Inc.

Extracellular vesicles (EVs) are emerging as powerful liquid biopsy biomarkers; however, translational progress is often limited by inefficient and variable EV isolation workflows. Genolution's advanced platform delivers standardized, high-throughput EV isolation, followed by sequential extraction of proteins, miRNA, or DNA derived from isolated EVs within a single integrated automated process. This case study highlights scalable multiomics cancer biomarker discovery with improved reproducibility, automation, and reduced hands-on time.

12:10 pm Networking Luncheon

12:50 Networking Dessert Break with Exhibit Viewing

PRECISION ONCOLOGY

1:20 Chairperson's Remarks
Susanne Munksted, Chief Precision Medicine Officer, Diaceutics

1:25 Talk Title to be Announced
Susanne Munksted, Chief Precision Medicine Officer, Diaceutics

1:40 Presentation to be Announced

1:55 PANEL DISCUSSION: Precision Oncology
Moderator: Susanne Munksted, Chief Precision Medicine Officer, Diaceutics
Panelists:
Ezra Cohen, MD, CMO, Oncology, Tempus Labs, Inc.
Ajay Gannerkote, President, Integrated DNA Technologies Inc.
Samraat Raha, President & CEO, Myriad Genetics

2:55 Sponsored Presentation *(Opportunity Available)*

3:20 Networking Refreshment Break with Exhibit Viewing

PLENARY KEYNOTE SESSION

3:50 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

3:55 Keynote Introduction *(Sponsorship Opportunity Available)*

4:00 Presentation to be Announced

4:30 PLENARY KEYNOTE PANEL DISCUSSION: The Tipping Point: CEOs on the Future of Precision Medicine



Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
As precision medicine accelerates across oncology, population health, and consumer diagnostics, industry leadership is critical to translating innovation into real-world impact. In this session, Mara Aspinall hosts a CEO panel for a candid discussion on the technologies reshaping early detection, decentralized testing, genomic architecture analysis, and the expanding role of AI in powering more accurate and accessible care.
Panelists:
Lisa Alderson, CEO, Adela, Inc.
Julia Cheek, CEO and Founder, Everlywell

5:15 Networking Welcome Reception with Exhibit Viewing

6:15 Close of Day

TUESDAY, MAY 5

8:00 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

8:35 Keynote Introduction *(Sponsorship Opportunity Available)*

8:40 PLENARY KEYNOTE PANEL DISCUSSION: Intelligence & Impact: The Age of Diagnostic Innovation





Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University
Diagnostics is entering a moment of rapid change, fueled by new technologies, evolving patient needs, and the growing influence of AI. In this keynote session, Mara hosts a panel of industry leaders to discuss how they are driving innovation within their own organizations—from advancing early detection to expanding decentralized testing and building smarter, AI-enabled laboratory systems. The conversation will explore the practical steps these leaders are taking today.
Panelists:
William G. Morice II, MD, PhD, President & CEO, Mayo Clinic Laboratories; Professor & Past Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic; Chair, American Clinical Laboratory Association Board of Directors
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Ajit Singh, PhD, CEO, Harbinger Health
Megann Vaughn Watters, Vice President, New Ventures & Strategic Alliances, Labcorp

9:20 Transition to Sessions

INNOVATION IN LIQUID BIOPSY: MRD, MCED, AND BIOMARKERS

9:25 Chairperson's Remarks
Catia Verbeke, PhD, Managing Director, L.E.K. Consulting

9:30 Presentation to be Announced

9:45 A New Biological Substrate for AI: Physically Enriched, Organ-Resolved Multiomics from Blood
Pierre Arsène, Founder & CEO, Mursla Bio
Advances in AI for precision medicine are increasingly limited by the quality, specificity, and biological relevance of available molecular data. We introduce a new biological substrate for AI: organ-resolved multiomics derived from physically enriched extracellular vesicles isolated directly from blood. This approach captures molecular cargo originating from defined tissues, reducing biological noise and revealing disease-specific signals that remain undetectable in bulk datasets, regardless of cohort size.

10:00 From Blood to Biology: Guiding Therapy across Chronic and Autoimmune Diseases
Diana Abdueva, PhD, Co-Founder & CEO, Aqtual, Inc.
Diana Abdueva, co-founder and CEO of Aqtual, will discuss how liquid biopsy, active chromatin cell-free DNA (cfDNA), and advanced biomarker analysis are expanding precision medicine beyond oncology into chronic and autoimmune diseases. She will highlight how transcriptomic, epigenetic, and protein-DNA signals from a simple blood draw can guide therapy selection, improve patient outcomes, and enable companion diagnostics.

10:15 Leveraging Multiomics and Machine Learning towards a Stepwise Approach to Multi-Cancer Screening
Jimmy ChengHo Lin, PhD, CSO, Freenome, Inc.
Early cancer discovery is challenging due to the heterogeneity of different cancers and even within cancers from the same organ. Freenome built a multiomics discovery platform that looks for signals along the entire central dogma—DNA, methylation, RNA, protein, immunoprofiling, extracellular vesicles, circulating cells, among others. During this talk, we will discuss clinical, scientific, and computational strategies that are critical to create the best products to benefit patients.

10:30 Networking Coffee Break with Exhibit Viewing

INNOVATION IN LIQUID BIOPSY: MRD, MCED, AND BIOMARKERS (CONT.)

11:10 Chairperson's Remarks
Catia Verbeke, PhD, Managing Director, L.E.K. Consulting

11:15 The Evolving MRD Landscape in Solid and Hematologic Cancers
Catia Verbeke, PhD, Managing Director, L.E.K. Consulting
MRD is becoming increasingly embedded in routine care across solid and hematologic cancers. This talk provides an overview of where MRD is gaining traction across tumor types and intervention points along the patient journey, spanning perioperative through surveillance settings. It will also outline key assay modalities (NGS, PCR, flow, etc.) and technology approaches (tumor-informed vs tumor-naïve) and highlight how MRD is shaping therapeutic development and trial design.

11:30 From Diagnosis to Monitoring: Liquid Biopsy across Cancer Care
Lisa Alderson, CEO, Adela, Inc.

11:45 PANEL DISCUSSION: Innovation in Liquid Biopsy: What's Next for MRD, Early Detection, and MCED?
Moderator: Catia Verbeke, PhD, Managing Director, L.E.K. Consulting
Liquid biopsy is becoming routine in oncology: MRD is scaling in key tumor types, single-cancer early detection is expanding beyond CRC, and MCED is gaining traction via alternative payment models (e.g., self-pay). Yet, further advances are needed to unlock the full potential of liquid biopsy to transform cancer care. This panel discusses the next wave of innovation.
Panelists:
Tomasz M. Beer, MD, CMO & Vice President, Multi-Cancer Early Detection, Exact Sciences
Mark Gardner, MBA, Senior Vice President, Molecular Genomics and Oncology, Quest Diagnostics
Taylor Jensen, PhD, Vice President, Head of Science, Oncology, Labcorp
Jean-Francois Martini, PhD, Senior Director, BioPharma Translational Strategy & Applications, Guardant Health

12:45 pm Transition to Lunch

12:50 Luncheon Presentation *(Sponsorship Opportunity Available)* **or Enjoy Lunch on Your Own**

1:15 Session Break

PRECISION MEDICINE BEYOND ONCOLOGY

2:00 Chairperson's Remarks

2:05 Precision Diabetes: Subtyping and Managing Glucose Dysregulation Using Continuous Glucose Monitoring
Michael Snyder, PhD, Stanford W. Ascherman Professor & Chair, Department of Genetics; Director, Center for Genomics & Personalized Medicine, Stanford University
Nutrition impacts all aspects of health and longevity, yet responses to food are highly personalized. Using Continuous Glucose Monitoring (CGM) we demonstrate that individuals have personalized glucose responses to different carbohydrates. We show that there are subtypes of glucose dysregulation (muscle insulin resistance, beta cell defect, incretin effects) and postprandial response and mitigation depends upon the dysregulation subtype. Lifestyle—food, activity, timing—correlate with glucose levels, enabling personalized management of glucose dysregulation.

2:20 The Role of Biomarkers and Future State of Precision Medicine Outside of Oncology
Arushi Agarwal, Partner, Health Advances LLC
Biomarkers to inform clinical decisions in non-oncology indications such as Alzhiemer's, Parkinson's Disease, and metabolic disorders are becoming increasingly important. These conditions are unique from oncology which presents numerous opportunities, as well as a number of challenges. This talk will focus on trends in the use of biomarkers, key challenges, and a call to action for industry stakeholders.

2:35 Enabling Precision Health at Scale for All
Carlos D. Bustamante, PhD, Founder & CEO, Galatea Bio

2:50 AI, Clinical Data, and Multiomics for Precision Health
Marina Sirota, PhD, Professor and Acting Director, Bakar Computational Health Sciences Institute, University of California, San Francisco

3:05 Precision Prevention: Shaping the Future of Longevity
Steve Gardner, PhD, CEO and Co-Founder, PrecisionLife
Steve Gardner will outline how AI-led combinatorial analytics is enabling a preventative approach to complex chronic diseases. By determining lifetime risk of disease; predicting individual response to treatments, including GLP-1s; and systematically identifying disease-resilient protective genes linked to healthier aging and resistance to neurodegeneration; PrecisionLife is demonstrating how mechanistic insights will power the revolution of proactive, personalized, and preventative care.

3:20 Precision Neurology
Doug Biehn, CEO, Octave Bioscience

3:35 BrainGeneBot: A GPT-Engineered Platform for Polygenic Risk Score Analysis and Interpretation in Alzheimer's Disease
Zhongming Zhao, PhD, Chair & Professor for Precision Health; Director, Center for Precision Health, University of Texas in Houston
Large-scale genetic and genomic datasets have transformed the study of complex diseases, yet heterogeneity across studies and the difficulty of translating statistical associations into biological insight limit their utility. Polygenic risk scores (PGS), widely used to quantify genetic risk for conditions such as Alzheimer's disease (AD), exemplify these challenges. Here, we present BrainGeneBot, a GPT-driven chat framework designed to connect complex genetic data with biologically meaningful interpretation.

3:50 AI and Epigenetics-Powered Precision Cardiovascular Medicine
Meesha Dogan, PhD, Co-Founder & CEO, Cardio Diagnostics, Inc.
The convergence of AI and epigenetics is redefining what's possible in cardiovascular medicine. Using AI, it is now possible to decode the dynamic molecular changes that reflect lifestyle impact alongside genetics to enable a new frontier in highly personalized prediction, prevention, and management of heart disease. This presentation will explore how the fusion of AI and epigenetics is delivering actionable intelligence for truly individualized cardiovascular prevention, diagnosis, and care optimization.

4:05 Close of Conference

Join Us in San Francisco

HOTEL & TRAVEL INFORMATION

Conference Venue and Hotel:
Hotel Nikko San Francisco
222 Mason Street
San Francisco, CA 94102

Discounted Room Rate: $229 s/d
Discounted Room Rate Cut-off Date: April 6, 2026

For hotel reservations, please go to the Travel Page of TriConference.com